经皮射频消融治疗乳腺癌肝转移疗效的Meta分析-现代医学

经皮射频消融治疗乳腺癌肝转移疗效的Meta分析

单位：1. 内蒙古科技大学包头医学院研究生院, 内蒙古包头 014040;
2. 内蒙古科技大学包头医学院第一附属医院医学影像科, 内蒙古包头 014010

分类号：R737

出版年·卷·期（页码）：2024·52·第四期（544-550）

摘要：

目的：通过采用Meta分析的方法来研究经皮射频消融(PRFA)治疗乳腺癌肝转移(BCLM)患者的不同年限总生存率(OS)、完全消融率(CA)、局部复发率(LTP)，以期获得PRFA治疗BCLM的临床疗效的循证医学相关依据。方法：系统检索PubMed、Cochrane library、Embase、中国知网、万方数据库从建库至2023年9月以来关于PRFA治疗BCLM的队列研究或病例对照研究。依据制定的纳入及排除标准来筛选文献，完成文献质量评价并提取数据，利用Stata 15.1软件进行统计分析并绘制森林图。结果：本研究共纳入10项病例对照研究及队列研究，PRFA治疗BCLM患者为312例，1、2、3、5年OS分别为 86%、57%、56%、33%，CA为94%，LTP为16%。结论：本Meta分析表明，PRFA治疗BCLM具有良好的疗效。

Objective: To study the overall survival rate(OS), complete ablation rate(CA), and local tumor progression rate(LTP) in different years after percutaneous radiofrequency ablation(PRFA) for breast cancer liver metastases(BCLM) by Meta-analysis, in order to obtain the basis of evidence-based medicine for the clinical efficacy of PRFA in BCLM. Methods: Cohort studies or case-control studies on PRFA in the treatment of BCLM were systematically searched from PubMed, Cochrane library, Embase, CNKI and Wanfang from database inception to September 2023. References were screened according to inclusion and exclusion criteria, quality assessment was carried out, and data were extracted. Stata 15.1 software was used for statistical analysis and forest map drawing. Results: A total of 10 case-control studies and cohort studies were included. A total of 312 patients were treated with PRFA for BCLM, with OS at 1, 2, 3 and 5 years of 86%, 57%, 56%, 33%, CA of 94% and LTP of 16%. Conclusion: The Meta-analysis indicates that PRFA is effective in the treatment of BCLM.

参考文献：

[1] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] LIANG Y,ZHANG H,SONG X,et al.Metastatic heterogeneity of breast cancer:molecular mechanism and potential therapeutic targets[J].Semin Cancer Biol,2020,60:14-27.
[3] RASHID N S,GRIBLE J M,CLEVENGER C V,et al.Breast cancer liver metastasis:current and future treatment approaches[J].Clin Exp Metastasis,2021,38(3):263-277.
[4] GERRATANA L,FANOTTO V,BONOTTO M,et al.Pattern of metastasis and outcome in patients with breast cancer[J].Clin Exp Metastasis,2015,32(2):125-133.
[5] ZUO Q,PARK N H,LEE J K,et al.Liver metastatic breast cancer:epidemiology,dietary interventions,and related metabolism[J].Nutrients,2022,14(12):2376.
[6] GIORDANO G,FEBBRARO A,QUAQUARINI E,et al.Eribulin treatment in patients with liver metastatic breast cancer:eight Italian case reports[J].Oncology,2018,94(Suppl 1):34-44.
[7] VOGL T J,FREICHEL J,GRUBER-ROUH T,et al.Interventional oncological treatment of breast cancer liver metastasis(BCLM):single center long-term evaluation over 26 years using thermoablation techniques like LITT,MWA and TACE in a multimodal application[J].Int J Hyperthermia,2023,40(1):2200582.
[8] 中国女医师协会乳腺疾病研究中心.中国进展期乳腺癌共识指南2020(CABC3)[J].癌症进展,2020,18(19):1945-1964.
[9] STANG A.Critical evaluation of the Newcastle-Otawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J].Eur J Epidemiol,2010,25(9):603-605.
[10] 徐娟,赵晔.射频消融联合化学治疗在乳腺癌肝转移中临床效果[J].医学研究杂志,2017,46(1):59-62.
[11] ABBAS H,ERRIDGE S,SODERGREN M H,et al.Breast cancer liver metastases in a UK tertiary centre:Outcomes following referral to tumour board meeting[J].Int J Surg,2017,44:152-159.
[12] TRESKA V,CERNA M,LISKA V,et al.Surgery for breast cancer liver metastases-factors determining results[J].Anticancer Res,2014,34(3):1281-1286.
[13] LEE H Y,KO H K,KIM S H,et al.Percutaneous radiofrequency ablation for liver metastases in breast cancer patients[J].Breast J,2013,19(5):563-565.
[14] MELONI M F,ANDREANO A,LAESEKE P F,et al.Breast cancer liver metastases:US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates[J].Radiology,2009,253(3):861-869.
[15] KVMLER I,PARNER V K,TUXEN M K,et al.Clinical outcome of percutaneous RF-ablation of non-operable patients with liver metastasis from breast cancer[J].Radiol Med,2015,120(6):536-541.
[16] LIVRAGHI T,GOLDBERG S N,SOLBIATI L,et al.Percutaneous radio-frequency ablation of liver metastases from breast cancer:initial experience in 24 patients[J].Radiology,2001,220(1):145-149.
[17] GUNABUSHANAM G,SHARMA S,THULKAR S,et al.Radiofrequency ablation of liver metastases from breast cancer:results in 14 patients[J].J Vasc Interv Radiol,2007,18(1):67-72.
[18] VELTRI A,GAZZERA C,BARRERA M,et al.Radiofrequency thermal ablation(RFA) of hepatic metastases(METS) from breast cancer(BC):an adjunctive tool in the multimodal treatment of advanced disease[J].Radiol Med,2014,119(5):327-333.
[19] BAI X M,YANG W,ZHANG Z Y,et al.Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer[J].Int J Hyperthermia,2019,35(1):183-193.
[20] NAGASAWA S,KUWANO A,TANAKA K,et al.Combined ultrasound and computed tomography guidance in radiofrequency ablation for hepatocellular carcinoma reduces local recurrence rate[J].Cancer Diagn Progn,2023,3(6):660-666.
[21] YANG G,WANG G,SUN J,et al.The prognosis of radiofrequency ablation versus hepatic resection for patients with colorectal liver metastases:a systematic review and meta-analysis based on 22 studies[J].Int J Surg,2021,87:105896.
[22] 尹娜,郭震,付金凤,等.3.0 T MRI 与 CT 对肝脏肿瘤射频消融术后局部疗效评价的比较[J].现代医学,2020,48(3):311-316.
[23] ERCOLANI G,ZANELLO M,SERENARI M,et al.Ten-year survival after liver resection for breast metastases:a single-center experience[J].Dig Surg,2018,35(4):372-380.
[24] 韩利杰.超声引导下肝转移瘤射频消融的临床应用意义分析[J].医学理论与实践,2021,34(4):612-614. 《现代医学》唯一投稿网址：www.xdyx.org.cn

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录